{"id":6280,"date":"2020-12-07T07:00:00","date_gmt":"2020-12-07T07:00:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-receives-new-vinnova-financing-to-increase-international-competitiveness\/"},"modified":"2020-12-07T07:00:00","modified_gmt":"2020-12-07T07:00:00","slug":"realheart-receives-new-vinnova-financing-to-increase-international-competitiveness","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-receives-new-vinnova-financing-to-increase-international-competitiveness\/","title":{"rendered":"Realheart receives new Vinnova financing to increase international competitiveness"},"content":{"rendered":"
This spring, the Swedish innovation agency Vinnova granted financing for Realheart's operations. The company is now launching another project that has received SEK 200,000 in financing, with the motivation that the project aims to create opportunity for international competitiveness and sustainable solutions to global societal challenges.<\/strong><\/div>\n

Earlier this week it was announced that Realheart has been granted SEK 200,000 by Vinnova within the strategic innovation program Medtech4Health. It is the same program that this spring supported another one of Realheart's projects. This time it is co-financing the competence enhancement in a project to further develop and refine the automatic control in Realheart's artificial heart. Vinnova's rationale for the financing is that "the project aims to create opportunity for international competitiveness and sustainable solutions to global societal challenges".<\/span><\/span><\/span><\/p>\n

The automatic control adapts the heart's pumping to match the body's needs, with the aim that the patient should be able to live a normal life even after the implantation of an artificial heart. It is deemed a crucial factor in creating an internationally competitive product.<\/span><\/span><\/span><\/p>\n

During the project, the automatic control will be tested in a human body simulator by Dr Libera Fresiello who is an advisor to the expert panel in medical devices and in vitro diagnostics at the European Commission Directorate – General for Health and Food Safety.<\/span><\/span><\/span><\/p>\n

\u201cWe are very grateful for the strategic innovation program Medtech4Health and its support in this project. It\u00b4s very much in line with the activities and goals we want to achieve. The support means that we can further strengthen Realheart's competitiveness with unique cutting-edge expertise that few people in the world possess. Furthermore, this is something that can be done despite the Corona pandemic's influence in the world. We will start the project immediately and our employees will work with full force going forward ", comments Realheart's CEO and founder Azad Najar.<\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/strong><\/span><\/p>\n

Azad Najar, CEO<\/span><\/span><\/p>\n

Phone: +46(0)736 673\u00a0463<\/span><\/span><\/p>\n

e-mail:\u00a0<\/span><\/span>azad.najar@realheart.se<\/span><\/span><\/a>\u00a0<\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. <\/span><\/span><\/em>Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. <\/span><\/span><\/em>A unique concept in the medical technology world.<\/span><\/span><\/em><\/span><\/span><\/p>\n

\u00a0<\/p>\n<\/div>\n